Duloxetine treatment of dysthymia and double depression: An open-label trial

Journal of Clinical Psychiatry

Volumn 68, Issue 5, 2007, Pages 761-765

  Koran, Lorrin M ^a,b   Aboujaoude, Elias N ^a   Gamel, Nona N ^a  

^a STANFORD UNIVERSITY MEDICAL CENTER   (United States)

^b STANFORD UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DULOXETINE; SEROTONIN UPTAKE INHIBITOR; THIOPHENE DERIVATIVE;

ADULT; ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DECREASED APPETITE; DEPRESSION; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DIARRHEA; DIZZINESS; DROWSINESS; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSTHYMIA; FATIGUE; FEMALE; HUMAN; INSOMNIA; LASSITUDE; MAJOR CLINICAL STUDY; MALE; NAUSEA; PRIORITY JOURNAL; REMISSION; SCORING SYSTEM; SIDE EFFECT; SOMNOLENCE; SWEATING; XEROSTOMIA; YAWNING; MAJOR DEPRESSION; MIDDLE AGED; PSYCHOLOGICAL ASPECT; TREATMENT OUTCOME;

ADULT; DEPRESSIVE DISORDER, MAJOR; DYSTHYMIC DISORDER; FEMALE; HUMANS; MALE; MIDDLE AGED; SEROTONIN UPTAKE INHIBITORS; THIOPHENES; TREATMENT OUTCOME;

EID: 34249669848     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.v68n0514     Document Type: Article

References (25)

1. Weissman MM, Leaf PJ, Bruce ML, et al. The epidemiology of dysthymia in five communities: rates, risks, comorbidity, and treatment. Am J Psychiatry 1988;145:815-819
2. Kessler RC, McGonagle KA, Zhao S, et al. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States: results from the National Comorbidity Survey. Arch Gen Psychiatry 1994;51:8-19
3. Friedman RA, Markowitz JC, Parides M, et al. Six months of desipramine for dysthymia: can dysthymic patients achieve normal social functioning? J Affect Disord 1999;54:283-286
4. Klein DN, Shankman SA, Rose S. Ten-year prospective follow-up study of the naturalistic course of dysthymic disorder and double depression. Am J Psychiatry 2006;163:872-880
5. Shelton RC, Davidson J, Yonkers KA, et al. The undertreatment of dysthymia. J Clin Psychiatry 1997;58:59-65
6. Dunner DL. Current therapeutic approaches for dysthymic disorder. Expert Rev Neurother 2003;3:119-125
7. Detke MJ, Lu Y, Goldstein DJ, et al. Duloxetine 60 mg once daily versus placebo in the acute treatment of major depression. J Psychiatr Res 2002;36:383-390
8. Sheehan DV, Lecrubier Y, Sheehan KH, et al. The Mini-International Neuropsychiatric Interview (MINI): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry 1998;59(suppl 20):22-33
9. Rush JA, Giles DE, Schlesser MA, et al. The Inventory for Depressive Symptomatology (IDS): preliminary findings. Psychiatry Res 1986;18:65-87
10. Skinner MH, Kuan HY, Pan A, et al. Duloxetine is both an inhibitor and a substrate of cytochrome P4502D6 in healthy volunteers. Clin Pharmacol Ther 2003;73:170-177
11. Rush AJ, Hiser W, Biles DE. A comparison of self-reported versus clinician-rated symptoms in depression. J Clin Psychiatry 1987;48:246-248
12. Guy W. ECDEU Assessment Manual for Psychopharmacology. US Dept Health, Education, and Welfare publication (ADM) 76-338. Rockville, Md: National Institute of Mental Health; 1976:218-222
13. Gwirtsman HE, Blehar MC, McCullough JP Jr, et al. Standardized assessment of dysthymia: report of a National Institute of Mental Health Conference. Psychopharmacol Bull 1997;33:3-11
14. Lingjaerde O, Ahlfors UG, Bech P, et al. The UKU side effects rating scale: a new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients. Acta Psychiatr Scand Suppl 1987;334:1-100
15. Ravindran AV, Guelfi JD, Lane RM, et al. Treatment of dysthymia with sertraline: a double-blind, placebo-controlled trial in dysthymic patients without major depression. J Clin Psychiatry 2000;61:821-827
16. Vanelle JM, Attar-Levy D, Poirier MF, et al. Controlled efficacy study of fluoxetine in dysthymia. Br J Psychiatry 1997;170:345-350
17. Thase ME, Halbreich U, Kocsis J, et al. A placebo controlled trial comparing sertraline and imipramine for the treatment of dysthymia. Arch Gen Psychiatry 1996;53:777-784
18. Dunner DL. Duration of euthymia in dysthymic patients. Am J Psychiatry 1999;156:1992-1993
19. Marin DB, Kocsis JH, Frances AJ, et al. Desipramine for the treatment of "pure" dysthymia versus "double" depression. Am J Psychiatry 1994;151:1079-1080
20. Klein DN, Taylor EB, Harding K, et al. Double depression and episodic major depression: demographic, clinical, familial, personality, and socioenvironmental characteristics and short-term outcome. Am J Psychiatry 1988;145:1226-1231
21. Haykal RF, Akiskal HS. The long-term outcome of dysthymia in private practice: clinical features, temperament, and the art of management. J Clin Psychiatry 1999;60:508-518
22. Rush AJ, Gullion CM, Basco RM, et al. The Inventory of Depressive Symptomatology (IDS): psychometric properties. Psychol Med 1996;26:477-486
23. Dunner DL, Hendrickson HE, Bea C, et al. Venlafaxine in dysthymic disorder. J Clin Psychiatry 1997;58:528-531
24. Hellerstein DJ, Batchelder ST, Little SAS, et al. Venlafaxine in the treatment of dysthymia: an open-label study. J Clin Psychiatry 1999;60:845-849
25. Clayton AH, Montejo AL. Major depressive disorder, antidepressants, and sexual dysfunction. J Clin Psychiatry 2006;67(suppl 6):33-37